Sizes of these terms reflect their relevance to your search.
How to specifically target oncogenic KRAS-driven cancers while sparing normal tissues remains an unmet need in cancer therapy. In this issue of JEM, Jiang et al. (2022. J. Exp. Med.https://doi.org/10.1084/jem.20210739) leveraged KRAS-induced iron addiction in cancer cells to design a clever drug delivery approach to enable selective inhibition of KRAS signaling in mutant KRAS tumors but not in normal tissues, offering a new strategy for treating this largely incurable disease. © 2022 Lei and Gan.
Citation
Guang Lei, Boyi Gan. Iron out KRAS-driven cancer. The Journal of experimental medicine. 2022 Mar 09;219(4)
Mesh Tags
Substances
PMID: 35262627
View Full Text
